Linking medicine and economics: Health economics and quality of life in haemophilia care

Haemophilia

Volumn 8, Issue 3, 2002, Pages 217-220

  Schramm, W ^a   Berger, K ^a  

^a Department of Haemostaseology and Transfusion Medicine ^*  (Germany)

Author keywords

Haemophilia care; Health economics; Quality of life

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; HEALTH CARE; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH ECONOMICS; HEMOPHILIA; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; RESOURCE ALLOCATION; STANDARD; ECONOMICS; HEALTH CARE ORGANIZATION; HEMOPHILIA A; REVIEW;

ECONOMICS, MEDICAL; HEALTH CARE RATIONING; HEMOPHILIA A; HUMANS; QUALITY OF LIFE;

EID: 0036588818     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2002.00639.x     Document Type: Article

References (24)

1. Schulenburg JM, Hoffmann C. Review of European guidelines for economic evaluations of medical technologies and pharmaceuticals. HEPAC 2000; 1: 2-8.
2. Aledort LM, Haschmeyer RH, Pettersson and the Orthopaedic Outcome Study Group. A longitudinal study of orthopaedic outcomes for severe factor-VIIIficient haemophiliacs. J Intern Med 1994; 236: 391-9.
3. Aznar JA, Magallon M, Querol F, Gorina E, Tusell JM. The orthopaedic status of severe haemophiliacs in Spain. Haemophilia 2000; 6: 170-6.
4. Bohn RL, Avorn J, Glynn RJ, Choodnovskiy I, Haschenmeyer R, Aledort LM. Prophylactic use of Factor VIII: an economic evaluation. Thromb Haemost 1997; 79: 932-7.
5. Ekert H, Brewin T, Boey W, Davey P, Tilden D. Cost-utility analysis of recombinant factor VIIa (NovoSeven) in six children with long-standing inhibitors to factor VIII or IX. Haemophilia 2001; 7: 279-85.
6. Miners AH, Sabin CA, Tolley KH, Lee CA. Primary prophylaxis for individuals with severe haemophilia: how many hospital visits could treatment prevent? J Int Med 2000; 247: 493-9.
7. Miners AH, Sabin CA, Tolley KH, Lee CA. Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease. J Int Med 1998; 244: 515-22.
8. Molho P, Rolland N, Lebrun T et al. The French Study Group: Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. Haemophilia 2000; 6: 23-32.
9. Smith PS, Teutsch SM, Shaffer PA, Rolka H, Eyatt B. Episodic versus prophylactic infusions for hemophilia A. a cost-effectiveness analysis. J Pediatr 1996; 129: 424-31.
10. Schramm W, Royal, Kroner B, et al. Clinical outcomes and resource utilization associated with haemophilia care in Europe. Haemophilia 2002; 8: 33-43.
11. Szucs T, Schramm W. The economics of replacement therapy. Hämostaseologie 1996; 16: 291-5.
12. Szucs T, Öffner A, Kroner B, Giangrande P, Berntorp E, Schramm W. Resource utilisation in haemophiliacs treated in Europe: Results from the European study on socioeconomic aspects of haemophilia care. Haemophilia 1998; 4: 498-501.
13. Löfqvist T, Nilsson IM, Berntrop E, Pettersson H. Haemophilia prophylaxis in young patients - a long-term follow-up. J Intern Med 1997; 241: 395-400.
14. Miners AH, Sabin CA, Tolley KH, Jenikinson C, Kinds P, Lee CA. Assessing health related quality-of-life in individuals with haemophilia. Haemophilia 1999; 5: 378-85.
15. Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years experience of prophylactic treatment in haemophilia A and B. J Intern Med 1992; 232: 2532.
16. Petrini P, Lindvall N, Egberg N, Blomback M. Prophylaxis with factor concentrates in preventing hemophilic arthropathy. Am J Pediatr Hematol/Oncol 1991; 13: 280-7.
17. Royal S, Schramm W, Berntorp E, et al. Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia 2002; 8: 44-50.
18. Van den Berg HM, Fischer K, Mauser-Bunschoten EP et al. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001; 112: 561-5.
19. Schramm W (ed.). Blood Safety in the European Community: An Initiative for Optimal Use 1999.
20. Troppoli S, Monica V, Linari S, Longo G, Morfini M, Messori A. Mulitvariate analysis of factors influencing quality of life and utility in patients with hemophilia. Haematologica 2001; 86: 722-8.
21. EuroQol Group Website. URL: http://www.qlmedorg/EUROQOL/EUROQOL.html.
22. The EuroQol Group. EuroQol - a new facility for the measurement of health related quality of life. Health Policy 1994; 16: 655-62.
23. Ware JE Jr, Kosnski M, Keller SD. SF-36 Physical and Mental Health Summary Scales: A Users Manual Boston, MA: The Health Institute, 1994.
24. Ware JE Jr, Sherbourne JD. The MOS 36-Item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992; 30: 473-83.